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ABSTRACT
Lactate Dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate in the
final step of anaerobic glycolysis. Many invasive tumors depend on an increased rate of glycolysis in
order to maximize their growth potential under hypoxic environments, a phenomenon known as the
“Warburg Effect.” By finding a way to inhibit LDH, contributions would be made towards the
management of cancerous cells by inhibition of their energy production.
Human LDH isoenzyme A was subcloned into an in-house vector (pET28a with a
PreScission cleavage site) and overexpressed in E. coli Tuner(DE3) cells as a fusion protein with
maltose binding protein (MBP) to increase solubility. The fusion protein was cleaved, purified, and
subjected to crystallization trials using the hanging drop vapor diffusion method.
Crystals of the binary complex of LDH-A with NADH were obtained, and conditions
continue to be optimized in order to increase crystal size and diffraction quality. Steady-state kinetic
characterization revealed Km(Pyruvate) to be 130 ± 19 µM and the specific activity to be 382 ± 16 U/mg.
The IC50 value for the known weak inhibitor oxamate was determined to be 65 ± 2 µM.
Future plans include high-throughput screening (HTS) for novel LDH-A inhibitors, cocrystallization of LDH-A with HTS hit compounds, and the structure-based design of potent and
specific inhibitors of this enzyme.
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1 INTRODUCTION
1.1

Background of Lactate Dehydrogenase

Lactate Dehydrogenase (LDH) is a glycolytic enzyme that catalyzes the conversion of
pyruvate and NADH to lactic acid and NAD+, or vice versa (Figure 1). The purpose of this pathway
is to regenerate NAD+, which can be reduced to NADH in the early steps of glycolysis. This
pathway is important for generating ATP in the absence of oxygen, and is a primary source of
NAD+ for anaerobic cells that rely on fermentation for energy.

Figure 1. Enzymatic reaction of lactate dehydrogenase
In most eukaryotic cells, the primary source of ATP is oxidative phosphorylation, which
requires oxygen; therefore, the previously mentioned pathway can be utilized when oxygen becomes
less abundant, such as during strenuous physical activity. Cancer cells tend to opt for this glycolytic
pathway in order to maximize their growth potential even in the presence of oxygen. This is known
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as the “Warburg effect.” The main reason this occurs is that, as cells become cancerous,
mitochondrial function ceases, triggering apoptosis in an effort to kill the cell. For cancer cells this
means that there must be another mechanism for obtaining energy to continue metabolism (4).
Finding a means to inhibit LDH would contribute significantly towards the management of
cancerous cells by inhibiting their energy production mechanism. LDH is expressed from three
different genes: ldha, ldhb, and ldhc. These genes are transcribed and translated to form the protein
subunits M, H, and the testis specific subunit, respectively. Upon translation, these subunits form a
tetramer which constitutes an active LDH enzyme. Various tissue types express different isoforms
of LDH-A, as the subunits arrange in different combinations. LDH-A (with four M subunits made
by the LDH-A gene) is most abundant in skeletal muscle, where glycolysis is required to meet
metabolic needs when oxygen is low during strenuous physical activity. LDH-B is most abundant in
cardiac muscle, and is used to continue energy production when oxygen levels decrease. LDH-C is
an isoform that is present in the testes and is required for spermatogenesis and sperm function.
Targeted disruption of LDH-C impairs fertility in male mice and was once considered specific to
male germs cells only (2). More recently, LDH-C was also found in tumors such as lung cancer,
melanoma, breast cancer, and prostate cancer (2).
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2 MATERIALS AND METHODS
•

Water from a Barnstead NANOpure Diamond purifying device from Thermo Scientific was
used for all applications.

2.1

Solutions and Media

2.1.1

Antibiotic stock solutions

Kanamycin (Kan):

Ampicillin (Amp):

30 mg/mL Kanamycin

100 mg/mL Ampicillin

Antibiotic stocks were purified using a 0.4 μm filter and were diluted 1:1000 when used.

2.1.2

Solutions for protein purification

Buffer A – NiNTA #1:

Buffer B – NiNTA #1 :

Desalting Buffer #1:

100 mM Na/K Phosphate

100 mM Na/K Phosphate

100 mM Na/K Phosphate

300 mM NaCl

300 mM NaCl

150 mM NaCl

20 mM Imidazole

250 mM Imidazole

1 mM DTT

pH 7.5

pH 7.5

pH 6.8

Buffer A – NiNTA #2:

Buffer B – NiNTA #2:

Buffer A – Q Sepharose:

100 mM Na/K Phosphate

100 mM Na/K Phosphate

50 mM Tris
13

300 mM NaCl

300 mM NaCl

1 mM EDTA

25 mM Imidazole

250 mM Imidazole

1 mM DTT

pH 6.8

pH 6.8

pH 7.5

Buffer B – Q Sepharose:

Gel Filtration Buffer:

Crystallization Buffer:

50 mM Tris

100 mM Phosphate

50 mM Tris

1 mM EDTA

150 mM NaCl

2 mM DTT

1 mM DTT

1 mM DTT

pH 8.0

400 mM KCl

pH 6.8

pH 7.5
ÆFPLC solutions were made using deionized water cooled to 4 °C. Following filtration
with a 0.45 μm filter, the pH was adjusted with 12 N HCl /1 N NaOH at 4 °C.

2.1.3

Growth media

2X YT broth (1L):

TB (900mL):

LB broth (1L):

LB-Agar(0.5L):

16 g tryptone

12 g tryptone

10 g tryptone

5 g (s) NaCl

10 g yeast extract

24 g yeast extract

5 g yeast extract

5 g tryptone

5 g NaCl

4 mL 100% glycerol

5 g NaCl

2.5 g yeast
10 g agar
14

500 mL water
Luria-Bertani (LB), 2x YT, and TB broths were prepared by combining the above components
and autoclaving the solution. Filter-purified antibiotic stocks were added prior to use, and unused
media was stored at 4 °C.
LB-Agar was prepared by mixing the components, then autoclaving the mixture to ensure
sterility and dissolve the agar. The agar was allowed to cool after autoclaving until it was roughly
30°C, and antibiotic stocks were added immediately prior to pouring plates to prevent
decomposition of the antibiotic by the heat. Plates were poured in a laminar flow hood.

2.2

Gel Electrophoresis

2.2.1

Horizontal DNA electrophoresis

1 % agarose gel (1):

50 X TAE (1L):

500 mg agarose

242 g Tris

50 mL 1X TAE

57.1 mL glacial acetic acid

1 μL (0.5 mM) ethidium bromide

50 mM EDTA pH 8.0

ÆThe gels were visualized with UV light.

2.2.2

12% Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE)

Solutions for forming the resolving and stacking portion of gels were stored at 4°C. 30%
acrylamide/bis-acrylamide was filter sterilized and stored in a dark bottle. Solutions for running and
15

visualizing gels were stored at room temperature. Gels were cast and run using the MiniPROTEAN 3 cell and casting module (Biorad, Hercules, CA).

Resolving portion(for 13 gels)

Stacking portion(for 13 gels)

Low range marker:

43.3 mL bis-acrylamide

7 mL bis-acrylamide

100 μL marker

36.2 mL H2O

33 mL H2O

200 μL 5X dye

27.1 mL 1.5M Tris-HCl pH 8.8

13.8 mL 0.5M Tris-HCl pH 6.8

700 μL water

1.1 mL SDS 10%

540 μL SDS 10%

Heat to 100 °C

900 μL APS

433 μL APS

Aliquot and store

100 μL TEMED

54 μL TEMED

10 X running buffer (1L):

Coomassie stain:

Destaining solution:

30 g Tris base

1.25 g Coomassie

50 % ethanol

144 g glycine

Brilliant Blue R-250

10% glacial acetic acid

10 g SDS

50 % ethanol
5 % glacial acetic acid

The resolving portion of the gel was cast and allowed to solidify before casting the stacking
portion. Gels were run for 1 h at 150 V in 1X running buffer, diluted from the 10X running buffer
above. Gels were stained for 15 min in Commassie and destained for several hours. Low range
molecular weight marker was used as a standard.
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Sample preparation for SDS-PAGE
5X Sample buffer:

Extraction buffer:

300 mM Tris

50 mM Tris-HCl (pH 8.0)

10% (w/v) SDS

1 mM EDTA

25% β-mercaptoethanol

0.1 M NaCl

50% glycerol

0.1% Triton X
1 mM dithiotheitol (DTT)

The sample buffer was adjusted to pH 6.8 using 12 N HCl, Bromophenol blue (0.05 %) was
added, and both sample buffer and extraction buffer were then stored at 4°C. Immediately prior to
use, DTT was added to the extraction buffer.
An aliquot (1 mL) of cells was collected from the culture in a microcentrifuge tube and
centrifuged for 1 min at 14,000 x g.

Following removal of the supernatant, the pellet was

resuspended in 250 μL extraction buffer and sonicated on ice (settings: duty cycle 100%, micro tip
4, pulsed sonication) for 15 sec. Following sonication, an 80 μL sample was taken (“total”=soluble
+ insoluble protein), and the solution was centrifuged for 1 min at 14,000 x g. A 80 μL supernatant
(soluble protein fraction) was then collected in a microcentrifuge tube as well. The total and soluble
samples were individually mixed with 20 μL 5X sample buffer, vortexed briefly, and heated to 95 °C
using a heating block for 5 min. 15-20 μL of sample were loaded into each lane of a 12 % SDSPAGE gel.

17

2.3

General Procedures

2.3.1

Protein concentration determination

Protein concentration was determined using Coomassie reagent (Pierce, Rockford IL) according
to the Bradford method (1), with a standard curve determined by measuring the visible absorption at
595 nm of bovine serum albumin (BSA) samples at concentrations of 0.5 mg/mL, 1.0 mg/mL, 1.5
mg/mL and 2.0 mg/mL at 596 nm. All absorption spectra were recorded using a Shimazdu UV2102PC spectrophotometer (Shimadzu, Colombia, MD).
The protein concentration of the standards and unknowns were determined as follows: a 5 μL
aliquot of protein was added to 95 μL water and 900 μL of Coomassie reagent in a 1.5 mL
microcentrifuge tube. The unknown protein was diluted as necessary to obtain a color similar to that
of the 1.0 mg/mL standard solution. Following 15 min incubation at room temperature, the
ultraviolet absorption of each sample in a polyethylene cuvette at 595 nm was recorded. The
spectrophotometer was zeroed against a solution containing only Coomassie reagent (900 μL) and
water (100 μL).

2.3.2

DNA concentration determination

DNA concentration was determined by adding 1 μL of DNA sample to a NanoDrop
instrument (Thermo Scientific, Wilmington, DE, USA) and measuring absorption at 260 nm.
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2.3.3

Transformation of CaCl2 competent cells

Cells were transformed by adding 1 μL (80 ng) of plasmid DNA to 100 μL of competent cells in
a pre-chilled 1.5 mL microcentrifuge tube. The mixture was incubated on ice for 30 min, heat
shocked for 45 sec at 42 °C, and re-incubated on ice for 2 min. 900 μL of LB broth was then added,
and the mixture was incubated in the shaker at 37°C for 1 hour. The cells were then centrifuged for
30 sec at 14,000 x g, and 900 μL of supernatant was removed. The pellet was resuspended in 100 μL
of the remaining LB broth and plated on LB agar plates containing the appropriate antibiotic(s). The
plates were incubated overnight at 37°C.

2.3.4

Preparation of glycerol stocks

An 800 μL aliquot of an overnight cell culture was combined with 200 μL of 80% glycerol and
stored at –80 °C for use in future experiments.

2.3.5

Plasmid preparation

Plasmids were collected and purified using the Mini-Prep Kit (Qiagen, Valencia, CA), according
to the manufacturer’s protocol, with the exception of a final elution volume of 30 μl of water. The
DNA samples were either used immediately or stored at -20 °C.

2.3.6

Sequencing

Amino acid sequences were analyzed by the Microbiology Core at Moffitt Cancer Center.

19

2.3.7

Cold shock induction protocol for expression of recombinant proteins from E. coli: large
scale
This procedure takes advantage of temperature-stressed cells with release of GroEL-GroES

chaperonins molecules. GroEL belongs to the chaperonin family of molecular chaperones and is
found in a large number of bacteria. It is required for the proper folding of many proteins. To
function properly, GroEL requires the lid-like cochaperonin protein complex GroES. Production of
high levels of chaperonins proteins can also be triggered by exposure to different kinds of
environmental stress such as temperature, infection, inflammation, and exposure of the cell to toxins
(ethanol, arsenic, trace metals, and ultraviolet light, among others). They play an important role in
protein-protein interactions, including folding and assisting in the establishment of proper protein
conformation (shape) and prevention of unwanted protein aggregation. By helping to stabilize
partially unfolded proteins, the chaperonins aid in transporting proteins across membranes within
the cell.

Transformation:
5-10 ng of DNA was used to transform 50-100 µl of competent cells [following the protocol
described above in section 2.3.3 in page 19], plating 100-150 µl on LB-agar and the appropriate
antibiotics.

Growth:
A single colony of the transformed cells was used to inoculate 300 mL of 2x YT medium
containing 0.4% glucose with the appropriate antibiotics. Incubate overnight at 37 °C (150-180 rpm
to ensure that cell density is not too high).
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Induction:
Autoclaved flasks containing TB-phosphate medium and appropriate antibiotics were
allowed to cool to 4 ºC. a) At the end of the growth phase, measure the density at 600 nm (you
should expect an OD600nm ~1.6-1.8); take 50 µL aliquot (this is your un-induced control).
b) Harvest the overnight cells culture by centrifugation (10 min, 6 K rpm, 4 °C) and resuspend the
cell pellet in 100 mL of pre-chilled (4 °C) Terrific Broth-phosphate medium, supplemented with the
appropriate antibiotics, [This step assures to induce the cells at saturation, taking advantage of
having the maximum number of cells possible before induction].
c) Subject the suspended cells to “cold shock” for 30 minutes (incubation in an ice-water bath, while
keeping the temperature of the bath below 10 °C), [this allows stress of the cells in preparation of
release of the chaperonin molecules).
d) At the end of the incubation period, aliquot equally the resuspended cells into the large scale
flasks (containing TB-phosphate/antibiotics). Add cold 100% Et-OH to make a final concentration
of 2% in the flasks (release of chaperonins). Induce the cells with 0.1-0.5 mM IPTG at 16-25 °C for
20 hours (250 rpm), or 44 hours at 10 ºC.
e) Measure the OD600nm at the end of the expression and withdraw an aliquot (this is your induced
cells control).

Harvesting:
Harvest the cells by centrifugation as above and wash with 15 mL/pellet of cold 1x PBS
(10 min, 6 K rpm, 4 °C).

RECIPES:
2x YT:
21

1L:

16 g Bacto-Tryptone
10 g Yeast Extract
5 g NaCl

Adjust pH to 7.0 with NaOH, adjust volume to 1 L with H2O. Sterilize by autoclaving and store at
room temperature.

TB-Phosphate 1L
900 mL:

12 g Bacto-Tryptone
24 g Yeast Extract
4 mL of 100% glycerol or 8 mL of 50% glycerol (recommended).

ÆSterilize by autoclaving and cool to < 60 °C.
ÆAdd 100 mL of sterile 10x TB phosphate* and store at room temperature.

•

[10x TB-posphate*: made by dissolving 23.1 g KH2PO4 (= 0.17 M) and 125.4 g K2HPO4 (=
0.72M) in 900 mL H2O. Adjust volume to 1Lwith H2O and sterilize by autoclaving. Store at
room temperature].

2.4

Protein purification – Fast Protein Liquid Chromatography (FPLC)
Proteins were prepared for purification by resuspending a cell pellet in extraction buffer (7.5 mL

buffer / 1.0 g of cells) with lysozyme (1 mg lysozyme / 1 g cells) and stirring for 1 h. The solution
was sonicated (settings: duty cycle 7, pulsed sonication) on ice for 2 x 30 sec. After sonication, the
solution was homogenized at 12,000 psi and 4°C. Following this cell lysis phase, the solution was
centrifuged for 30 min at 14,000 rpm and a sample was taken.

22

The supernatant following centrifugation was purified at 4 °C using an ÄKTA FPLC system
(Amersham Biosciences, Piscataway, NJ). The first purification step utilized a Nickel-nitriloacetic
acid (NiNTA) column (affinity chromatography), which was equilibrated using Buffer A – NiNTA
#1. After washing with 8 column volumes (CV) of Buffer A, unspecifically bound impurities were
eluted by 3 CV of 30% Buffer B – NiNTA #1 (containing a small amount of imidazole), then the
protein was eluted with 3 CV of 100% Buffer B – NiNTA #1 (higher imidazole content). Fractions
were analyzed for protein presence using SDS-PAGE. Those containing target protein were
combined and concentrated using an Amicon device (Fisher Scientific, Chicago, IL) with a 30 kD
filter (Millipore, Bedford, MA) and desalted with Desalting Buffer #1 using a Sephadex column.
The sample was then cleaved overnight (~16 h) with PreScission protease in a 20:1 (MBP-LDHA : PreScission) ratio. This cleaved protein solution was then concentrated to 2 mg/mL using the
same Amicon and desalted into Buffer A – NiNTA #2 using the same Sephadex column. Fractions
containing protein were then pooled and concentrated to 3 mg/mL. This protein was subjected to a
second NiNTA purification, equilibrated with Buffer A – NiNTA #2. Protein was eluted by
increasing the imidazole concentration in the mobile phase over 1 CV via a gradient from 0-100%
Buffer B – NiNTA #2. Following SDS-PAGE analysis, fractions containing the protein were
pooled, concentrated, and desalted into Buffer A – Q-Sepharose. This sample was then loaded on a
Q-Sepharose (anion exchange) column (CV=5 mL), and the protein was eluted by increasing the salt
concentration via a gradient from 0-100% Buffer B – Q-Sepharose. Fractions containing protein
were pooled, concentrated to 5 mg/ mL, and loaded onto a Sephadex 200 column that had been
equilibrated with gel filtration buffer. After this column, protein samples were concentrated to
7 mg/mL and stored in 2 mL aliquots at –80 °C after shock freezing with liquid N2.
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PD-10 desalting columns (Amersham Biosciences) were used to desalt the protein in preparation
for crystallization. The columns were equilibrated with crystallization buffer, and a 2.5 mL aliquot of
protein was loaded onto the column and eluted with 3.5 mL of the crystallization buffer according
to the manufacturer’s protocol. The columns were re-equilibrated with 15 – 25 mL of buffer prior to
re-use if more protein was to be purified. The eluted protein was concentrated with Centricon
devices with a 30 kD cutoff (Millipore, Bedford, MA). Approximately 2 mL of protein was added to
the Centricon device and centrifuged for 25 min at 4,000 rpm and 4 °C. Flow-though was discarded,
and the device was refilled and centrifuged for 25 min repeatedly until all the protein had been
added to the device, at which point it was centrifuged for to concentrate the sample.

2.5

Crystallization
Prior to crystallization, NADH was added, and the protein sample was diluted to 15 mg/ mL.

The protein was then crystallized via vapor-diffusion method as a 1:1 sitting drop crystal screen with
buffers from Index (Hampton Research, Laguna Niguel, CA). Wells that showed promising
conditions were optimized using a VDX 24 well plate (Hampton Research) and a 22 mm siliconized
glass coverslide (Hampton Research) for hanging-drop vapor-diffusion method.

2.6

Enzyme kinetics of LDH-A
The enzymatic activity of LDH-A was measured in a 1 mL reaction with 0.25 μg/mL LDH-A (7

nM), 200 µM NADH and varying concentrations of pyruvate from 12.5-120 µM. A 50 mM
phosphate buffer (pH 6.5) was used. A table corresponding to the setup of these reactions is
included below (Table 2-2), and the final concentrations for the changing variable (pyruvate) are
listed in Table 2-1 A. After determining the Km of pyruvate to be 129.6 µM, this concentration was
24

used when performing experiments to find the IC50 value for oxamate, a weak inhibitor. Table 2-3
details the kinetics experiments performed to find the IC50 of oxamate, while Table 2-1 B shows the
final concentrations of the changing parameter (oxamate) of this experiment.
Table 2-1. Final concentrations in the reactions for Km measurement and IC50 measurement.
Assay
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

A. Pyruvate concentration (µM)
in pyruvate Km measurement
12.5
25
50
100
150
200
300
400
600
800
1200

B. Oxamate concentration (µM)
in oxamate IC50 measurement
0.39
1.56
3.125
6.25
12.5
25.0
50.0
100.0
200.0
400.0
500.0
600.0
800.0
1000.0
1200.0
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Table 2-2. Pipetting protocol and portions for measuring activity of LDH-A.
Assay
number:

Quantity
(μL) of 20
mM NADH

Concentration
of pyruvate
(mM;
changing
variable)

Quantity of
Buffer (μL)

Quantity of
0.025 mM
LDH-A (μL)

Total
reaction

1-11

10 μL

1.25-120

970 μL

10 μL

1 mL

Table 2-3. Pipetting protocol and portions for measuring of IC50 of LDH-A using oxamate.
Assay
Quantity of
Quantity
Quantity
Concentration Concentratio
Number
Buffer (μL) (μL) of 12.96
(μL) of 20
of Oxamate
n of Inhibitor
µM Pyruvate mM NADH (nM; changing
(nM)
variable)
1-15

960

10

10

3.9-120

10

Absorbance was measured at 340 nm using a UV-1650PC UV-Vis spectrophotometer from
Shimadzu (Columbia, MD, USA).
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3 RESULTS
3.1

Lactate Dehydrogenase Subcloning #1

The ldha gene was purchased from GENEART (Regensburg, Germany) in a pGA4 (ampicillinresistant) cloning vector backbone (Figure 3-1). The gene was amplified using E. coli DH5α cells, and
the DNA was isolated using a Qiaprep Miniprep kit (Qiagen, [location?]). The sample concentration
was then measured using a NanoDrop (Thermo Scientific,Wilmington, Delaware). LDH-A was
subcloned into three vectors with different tags: MBP-pET28a (an in-house modified pET28a
vector with MBP tag), pET28a-PreScission, and pGEX-6P-1. The gel showed that the digestion
reactions went to completion (Figure 3-2), which was confirmed by DNA sequencing performed by
the Moffitt Cancer Center’s molecular biology core facility.

Figure 3-1. GENEART LDH-A in pGA4 DNA construct. This is the vector map
supplied by GENEART illustrating the pGA4 plasmid containing the ldha gene optimized for
expression in E. coli.
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Figure 3-2. LDH-A-pGA4, MBP-pET28a, pET28a-PreScission, and pGEX-6P-1 digestion
reaction gel. The gel shows a complete digestion reaction for all samples.

3.2

Overexpression studies
After ligation of LDH-A into MBP-pET28a, pET28a-PreScission (His6), and pGEX-6P-1

expression vectors, overexpression studies were performed to find suitable conditions for soluble
LDH-A. LDH-A in the MBP-pET28a vector, which includes a His6 tag, was transformed into
Tuner(DE3) E. coli cells, and overexpression studies at 37°C and 16°C were attempted, using
0.5 mM IPTG to induce expression. (Figure 3-3 and Figure 3-4).
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Figure 3-3. LDH-A- MBP at 37°C with 0.5mM IPTG. Lane 1: marker; Lane 2: control
(before induction with IPTG), total lysate; Lane 3: control, soluble lysate; Lane 4: induced sample
after 3 h of protein growth, total lysate; Lane 5: induced sample, soluble lysate. A second clone was
induced to provide a second control and is shown in lanes 6 and 7 as total and soluble protein,
respectively. The control lanes show bands corresponding to Negative controls show LDHA, so the
cell is leaky and there is a very small amount of soluble LDH-A can be obtained.
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Figure 3-4. LDH-A- MBP at 16°C with 0.5 mM IPTG. The lanes for this gel correspond to
those in Figure 3-3, except that these samples were induced and grown at 16°C. Again, leakage and
poor solubility are observed.
Following these results, LDH-A overexpression studies were set up using the cold shock
method. Results are shown in Figure 3-5.
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Figure 3-5. LDH-A- MBP overexpression using cold shock method with 0.5mM IPTG.
Lane 1: marker; Lane 2 and lane 3: are the controls; Lane 4 and lane 5 cold shock induced samples
grown overnight. The cells are slightly leaky, suggesting that the protocol can be optimized.
Protein overexpression studies were next performed using the LDH-A-pGEX-6P-1 construct,
containing a GST-tag, in E. coli Tuner (DE3) cells. Results are shown in Figures 3-6 and 3-7.
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Figure 3-6. GST-LDH-A overexpression using various concentrations of IPTG.
C=control, T=total, S=soluble. Cells did not show leakage but exhibited overexpression. However,
the protein did not appear to be soluble.

Figure 3-7. GST-LDH-A overexpression using various IPTG concentrations. Lower
IPTG concentrations were used in order to see if soluble protein would be overexpressed. No
solubility was observed.
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Next, protein overexpression studies were performed using the LDH-A-pET28a (His6-tag)
vector in E. coli BL21(DE3) and E. coli BL21(DE3) pLysS cells by inducing with 0.5 mM IPTG and
growing at 37°C and 16°C. Results are shown in Figure 3-8.

Figure 3-8. His6- LDH-A overexpression using 0.5mM IPTG at 37°C and 16°C. The
labeled gel shows the cells are either leaky without soluble protein, or just without soluble protein.
Expression studies were then carried out using cold shock induction with various IPTG
concentrations in both BL21 (DE3) and BL21 (DE3) pLysS cells. Results are shown in Figure 3-9
and Figure 3-10, although no promising results were found.
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Figure 3-9. His6 - LDH-A overexpression in BL21(DE3) by cold shock induction studies
using 0, 0.1, and 0.5 mM IPTG. All cells show leakage despite the variations in IPTG and
overexpression.

Figure 3-10. His6 - LDH-A overexpression in BL21(DE3) pLysS by Cold Shock induction
studies using 0, 0.1, and 0.5 mM IPTG. This cell strain also shows leakage at all IPTG
concentrations.
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In summary, the only promising results found were using the LDH-A-MBP overexpression
using a modified cold shock method with 0.5 mM IPTG, so the subcloning was repeated to ensure
that the protocol was reproducible and to confirm and optimize the expression.

3.3

Subcloning #2
Agarose gel results for the digestion reaction of the repeat subcloning are shown in Figure 3-11,

with the final recombinant DNA construct shown in Figure 3-12. After ligation, the sequence was
verified by the Moffitt Cancer Center Molecular Biology core facility.

Figure 3-11. LDH-A and MBP-pET28a DNA preparations. A) LDH-A plasmid DNA; B
and C) LDH-A digested with BamHI and NotI restriction enzymes; D) 1 kbp DNA marker; E and
F) MBP-pET28a vector digested with BamHI and NotI; G) undigested MBP-pET28a plasmid
(control).
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Figure 3-12. Recombinant LDH-A DNA construct with MBP. This is a map of the DNA
construct used to produce His6-MBP-LDH-A.

3.4

Large scale protein overexpression
After comparing the results from multiple induction studies, LDH-A in fusion with MBP-His6 in

the pET28a vector and E. Coli Tuner (DE3) cells was chosen for large scale production of LDH-A.
Unfortunately, Although, when scaling the LDH-A over expression from a small scale to a large
scale using the cold shock method, the protocol did not appear to work, and LDH-A was not
expressed. The protocol was then further modified by scaling up the overnight starting culture (in 2
xYT) to a large scale, as opposed to the regular protocol using which a small scale of 2 xYT is grown
overnight and cold shocked, then inoculating in a large scale[4 L] of TB medium. The product, as
analyzed by SDS-PAGE analysis, is shown in Figure 3-13.
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Figure 3-13. Large scale overexpression of LDH-A. First lane shows the marker. Second and
third lane show the total and supernatant protein prior to induction. The fourth and fifth lane are
total and soluble LDH-A over expressed with 0.25mM IPTG using the cold shock procedure. The
gel shows highly overexpressed and soluble LDH-A, so the protocol was deemed appropriate to
proceed to the next step.

3.5

Protein purification – Fast Protein Liquid Chromatography (FPLC)
LDH-A was purified as described in section 2.4, following the purification steps summarized in

Figure 3-14.

37

Figure 3-14. Flow chart of protein purification. The major steps of the purification are
shown, skipping omitting the desalting steps.

The resulting FPLC elution profile and SDS-PAGE gel from the first NiNTA column is shown
as Figure 3-15; the second NiNTA column in Figure 3-16; the Q-Sepharose column in Figure 3-17;
and the Superdex 200 column in Figure 3-18.
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Figure 3-15. Elution profile of NiNTA column #1. Gel shows that the first peak is a mixture
of LDH-A and other impurities, while the second peak contains a high concentration of our target
protein (LDH-A).
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Figure 3-16. Elution profile of NiNTA column #2. Flowthrough fractions contain a mixture
of the cleaved maltose-binding protein tag and untagged LDH-A, while the elution peak shows fairly
pure LDH-A with a small quantity of free MBP tag.
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Figure 3-17. Elution profile of Q Sepharose column. The elution profile and gel confirm that
most of the protein comes out with the peak.
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Figure 3-18. Elution profile of Superdex 200 column. The elution profile shows where the
quaternary LDH-A protein is eluted using a gel filtration column.

A summary gel of the purification in Figure 3-19, with the corresponding protein content
tracking table listed as Table 3-1.
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Figure 3-19. LDH-A purification overview. Molecular weight marker, crude sample, sample
after the first NiNTA column, overnight cleavage reaction result, sample after the second NiNTA,
sample after Q Sepharose column (anion exchange), and pure LDH-A protein sample after
Superdex 200 column (size exclusion).
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Table 3-1. Summary of protein content. Protein concentrations and quantities as determined
throughout the multiple purification steps.

His‐MBP‐LDH‐A purification
1
2
3
4
5
6
7
8
9
10
11
12
13

3.6

Cell Pellet
Crude Extract (Cell Lysis
Supernatant)
NiNTA Pool
NiNTA Pool concentrated
LDH‐A pre‐cleavage reaction
LDH‐A post‐cleavage reaction
LDH‐A post‐cleavage reaction
concetrated
Desalted for NiNTA2 (8mL)
Desalted for NiNTA2 (8mL)
concentrated
NiNTA 2 pool
Q Sepharose load
Superdex 200 pool
Superdex 200 pool concentrated

Protein
Concentration
(mg/mL)
‐

Volume
(mL)

Total
Protein
(mg)
40g

14.400
0.449
1.195
0.53
0.520

170.0
190.0
70.0
150.0
150.0

2448.0
85.3
83.7
79.5
78.0

100.0
3.5
3.4
3.4
3.2

2.000
0.707

39.0
108.0

78.0
76.4

3.2
3.1

3.208
1.027
16.000
0.201
5

23.0
70.00
2.00
50.00
2

73.8
71.9
32.0
10.1
10

3.0
2.9
1.3
0.4
0.4

% YIELD

Protein Crystallization

LDH-A was desalted into 50 mM Tris a of pH 7.0 using a PD-10 desalting column, and was
concentrated to 14 mg/ mL using Centricon. In order to find crystallization conditions for LDH-A
complexed with NADH bound, the Index crystal screen (Hampton Research, CA) was used. Each
droplet contained 1 μL protein and 1 μL crystal screen solution. Plates were incubated at 19 °C and
checked at intervals of 1, 2, and 4 days, and 1, 2, and 4 weeks. Crystals formed within the first two
days of incubation and continued to grow slightly as time passed. The conditions in which good
crystal growth was observed contained 0.1 M magnesium formate dihydrate with 15% PEG, as

44

shown in Figure 3-20, or 0.1 M succinic acid pH 7.0 and 15% PEG. The succinic acid condition was
f using the hanging drop method; results are shown in Figure 3-21.

0.5 mm

Figure 3-20. Crystals in 0.1 M magnesium formate dihydrate with 15% PEG.

0.5 mm

Figure 3-21. Crystals in 0.1 M succinic acid pH 7.0 and 15% PEG.
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3.7

Enzyme kinetics of LDH-A

Steady-state kinetic characterization revealed Km

(Pyruvate)

to be 130 ± 19 µM and the specific

activity to be 382 ± 16 U/mg, as shown in Figure 3-22. The IC50 value for the weak inhibitor
oxamate was determined to be 65 ± 2 µM, shown in Figure 3-23. The literature value for Km (pyruvate)
is 158 µM, and IC 50 of oxamate is 26 µM (3). These values match very well with measured values.

Specific Activity (U/mg)

400

300

200

100

0
0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

[Pyruvate] (mM)

Figure 3-22. Graph used to determine values for Vmax and Km(pyruvate). The data points were
fit into the Michaelis-Menten Equation.
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1.2

Relative activity
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Figure 3-23. IC50 of oxamate and the variation between data points. The data points were

fit into:
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4 DISCUSSION
Despite being one of the most studied enzymes and a model enzyme for explanation of
biochemistry concepts, much remains to be known about altering the activity of lactate
dehydrogenase for clinical purposes. As a part of this thesis project, the ldha gene was subcloned
into a vector, transformed into bacterial cells, overexpressed, purified, crystallized, and biochemically
characterized. This process required a large amount of effort as conditions needed to be found and
optimized at each step of the process.

4.1

Subcloning and overexpression studies

The ldha gene was subcloned into MBP-pET28a, pET28a-PreScission, and pGEX-6P-1. MBPpET28a was the first to be transformed into E. Coli Tuner (DE3) cells. Overexpression studies were
performed, as shown in Figures 3-2, 3-3, and 3-5, and overexpression of LDH-A was observed.
However, only cold shock induction showed results that were promising enough to continue, with
protein only overexpressed in samples that were induced with IPTG. One of the ways to reduce
leakiness is to grow the cell culture at a lower temperature but using cold shock induction the
temperature is as low as it can be, and these are the only suitable conditions found.
Other conditions were tried as well, including the pGEX-6P-1 vector in E. coli Tuner (DE3) cells
with different IPTG concentrations and growth conditions shown in Figure 3-6 and Figure 3-7, but
leakiness was observed and no soluble LDH-A was obtained. Poor results were also obtained when
using the pET28a-PreScission vector with BL21 (DE3) and BL21 (DE3) pLysS cells, as shown in
Figures 3-8, 3-9, and 3-10.
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4.2

Large scale protein overexpression
As the only promising conditions appeared to be the LDH-A-MBP-pET28a construct in E. coli

Tuner (DE3) using cold shock induction with 0.5 mM IPTG, subcloning was repeated. The same
results were shown for overexpression, so this was scaled up to a large scale LDH-A cell culture.
However, corresponding levels of overexpression were not observed, and SDS-PAGE analysis
showed only a very small amount of protein in the soluble portion.
When doing overexpression with cold shock induction, a 50 mL culture of cells in 2xYT media
are cold shocked, and all of the cells are resuspended in 50 mL of TB media. All cells that have been
cold shocked have chaperone proteins induced by the cold shock, which helps them produce soluble
LDH-A. However, when overexpressing a protein on a large scale using cold shock induction, six
flasks of 50 mL 2x YT overnight culture are grown, cold shocked, and aliqouted into 6 flasks with
660 mL TB media to be induced in. I concluded that, as not all cells were cold shocked and allowed
to focus solely on overexpression, this standard large scale cold shock protocol was not effective for
LDH-A production.
Cold shock induction for a large scale was therefore modified to match the growth conditions of
the expression studies. The overnight culture in E. coli Tuner (DE3) cells in 2x YT media was scaled
up to 6 flasks of 660 mL each, and each portion was cold shocked and aliquoted in 660 mL of TB
media. After all the cells in the TB media were cold shocked and the starting OD600 was
approximately 3, all of the cells should be able to focus on overexpression instead of growth. The
OD600 at harvest was approximately 5, and SDS-PAGE analysis showed good overexpression and
solubility. The protocol was shown to be reproducible in growing cell pellets for subsequent
purification.
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4.3

Protein purification – fast protein liquid chromatography (FPLC)
LDH-A was purified as in section 2.4, but the protocol required modifications to three earlier

purification protocols as certain buffer conditions and columns proved ineffective in the process.
The purification protocol that was used is summarized in Figure 3-14.
The purification was started with a nickel-nitriloacetic acid (NiNTA) affinity column which
binds imidazole residues, making it the perfect affinity column for a protein tagged with six histidine
residues. After loading the crude cell lysate, His6-LDH-A-MBP fusion protein was eluted in a two
step gradient with 30% NiNTA1 Buffer B in the first step and 100% NiNTA1 Buffer B in the
second step of the gradient. As shown in Figure 3-15, the flowthrough did not contain any of the
desired protein, the proteins from the first step of the gradient were impurities with a small amount
of LDH-A which apparently did not bind tightly to the column, and the eluate from the second step
gradient was fairly pure LDH-A.
After the first NiNTA column, the protein was cleaved with PreScission enzyme to yield His6LDH-A and MBP-tag, and the two proteins were separated using a second NiNTA column. The
elution profile and SDS-PAGE gel are shown in Figure 3-16. The flowthrough shows a mixture of
LDH-A and MBP that does not bind to the column. As it was assumed that LDH-A should bind
and this portion did not, it was thought to be improperly folded LDH-A. The eluate peak shows
that the earlier tubes contain pure LDH-A, while the later fractions contain MBP. This tells us that
there is some unspecific binding between the two proteins, and more purification steps are required.
The pool from the second NiNTA column was desalted, concentrated, and loaded into a QSepharose column. This column is an anion exchage column, meaning it will bind negatively charged
proteins, and elute . The pI of His6-LDH-A is 5.24, while the pI of MBP is 8.46, therefore, the
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buffer pH was set at 7.5 in order to result in negatively charged LDH-A and neutral MBP. The
elution profile for this step is shown in Figure 3-17, showing that MBP is in the flowthrough, along
with a small amount of uncharged LDH-A [??]. The elution portion, however, shows a very clean
LDH-A portion that was pooled, concentrated, and loaded into a gel filtration column.
The elution profile from the Superdex 200 gel filtration column is shown in Figure 3-18 and
shows a single peak with no aggregated LDH-A. Since the size of the LDH-A tetramer is
approximately 144 kD, the sample eluted out at the corresponding 204 mL, as expected. The
fractions were pooled, concetrated, frozen and stored at -80 °C. The LDH-A purification overview
gel can be seen in Figure 3-19, and a purification table is shown as well (Table 3-1).

4.4

Protein Crystallization

The crystallization process was fairly straightforward, and only training on how to set up the
robot was required. The Index screen from Hampton Research was used in order to screen for
crystallization conditions, and the protein concentration was set at 14 mg/ mL; slightly less than the
standard Schönbrunn lab protocol because very little protein was available from the purification.
After the conditions with the most promising crystals were found, they were further optimized by
using the same buffer conditions in a 1:1 hanging drop plate. This method normally results in larger
crystals with better growth? The resulting crystals are shown in Figure 3-15. These crystrals will be
measured in the future, and the molecular structure will be solved using molecular modeling.
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4.5

Enzyme kinetics of LDH-A

Steady-state kinetic experiments were performed to elucidate the activity of the purified protein.
After determining the specific activity, the affinity (Km) of pyruvate for LDH-A was derived. Using
this information, the pyruvate concentration was maintained at a constant level to elucidate the IC50
value of oxamate, a known weak inhibitor of LDH-A. The literature value for Km (pyruvate) is 158 µM,
which is a relatively small deviation from the measured value of 126 µM. The liturature IC50 of
oxamate is 26 µM, which also does not vary much from our measured value of 64.8 µM. This shows
that the protein that was used is close to optimal shape.
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5 CONCLUSION
The overexpression and purification of LDH-A are highly reproducible and provide a solid
basis for drug discovery methodology with this protein. Future plans include high-throughput
screening (HTS) for novel LDH-A inhibitors, co-crystallization of LDH-A with HTS hit
compounds, and structure-based design of potent and specific lead inhibitors of this enzyme.
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